drugset / Trial / NCT06093672

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672

Phase 3 Recruiting 220 enrolled Italfarmaco PPD Development, LP · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.

Timeline

Start
2024-03-26
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Givinostat Small molecule 50 mg Oral
Comparator Hydroxyurea Other / unclassified 500 mg Oral